Healthcare
NIOX GROUP PLC(CSSPF)
Live Price
Offline$0.7997
+0.00% today
1Y Change
-13.08%
Window
Jun 27, 2025 โ Jun 16, 2026
- Market Cap
- $280.00M
- Revenue Growth
- +16.5%
- EPS Growth
- +92.0%
- Dividend Yield
- 1.9%
Coverage: 249 bars ยท Jun 27, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NIOX GROUP PLC (CSSPF) is a Healthcare stock with a market cap of $280.00M and listed on OTC. The stock last traded around $0.80 and down 13.1% across the available one-year price window (Jun 27, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +16.5%, EPS growth of +92.0%, a dividend yield of 1.9%. What stands out right now is revenue +16.5%, EPS +92.0%, free cash flow -3.7% with operating margin 22.0% and ROIC 9.7%. The dividend is present but secondary, with a yield around 1.9%. Valuation already assumes a fairly strong business story at P/E 39.6 and price/sales 5.7. Stock Foundry combines CSSPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.5% vs +7.6% peer median
Operating Margin
Above sector median
+22.0% vs +19.4% peer median
P/E
Above sector median
39.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 24, 2026 with revenue below estimates by -0.1%.
The operating story is still moving forward
Revenue is running at +16.5% and EPS at +92.0%, with operating margin around 22.0%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 10, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 24, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Apr 1, 2025 | โ | +0.0% | +0.0% | +0.0% |
2024 Sep 24, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CSSPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSSPF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSSPF Max Drawdown
-13.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSSPF and SPY.
Company Overview
NIOX GROUP PLC
OTC
NIOX Group plc is a British public limited company specializing in medical devices for the diagnosis and management of respiratory diseases, particularly asthma. It develops and manufactures point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement devices, including the NIOX VERO and FeNO by NIOX range, which help healthcare professionals assess airway inflammation through simple, user-friendly tests aided by visual and audio cues. Founded in 2006 as Circassia Group and rebranded in 2022, the company is headquartered at The Oxford Science Park in Oxford, United Kingdom, with direct operations in the UK, US, Germany, Sweden, and China, plus a global distribution network spanning over 50 countries. NIOX Group plc reported ยฃ41.8 million in revenue for 2024, primarily from its NIOX products, with sales distributed across Asia Pacific, the United States, the EU, and the UK. Led by Executive Chairman Ian Johnson and CEO Jonathan Emms, it emphasizes corporate responsibility, ethical compliance, diversity, and environmental sustainability in its operations within the highly regulated medical diagnostics sector.
- Leadership
- Mr. Jonathan Charles Emms
- Employees
- 97
- Street Address
- Magdalen Centre, 1 Robert Robinson Ave The Oxford Science Park
- Mailing
- Oxford, OX4 4GA
- Region
- Oxford, United Kingdom
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 39.6
- EV/EBITDA
- 19.8
- Price/Sales
- 5.7
- Price/Book
- 3.8
Growth
- Revenue
- +16.5%
- EPS
- +92.0%
- Free Cash Flow
- -3.7%
Profitability
- Gross Margin
- 60.8%
- Operating Margin
- 22.0%
- Net Margin
- 14.4%
- ROE
- 10.1%
- ROIC
- 9.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.81
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.